RecruitingPhase 3NCT07132827

Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

280 participants

Start Date

Aug 28, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP)

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-1905 Injection and a drug called SHR-1905 Placebo Injection for people with chronic rhinosinusitis with nasal polyps. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.